Two prospective studies of psychiatric inpatients (including 7 mood disorder patients and 40 MDD patients) established that treatment with suvorexant (another kind of dual hypocretin antagonist) and different doses of seltorexant (a hypocretin-2 receptor antagonist) resulted in overall improvement in the quality of sleep as well as a reduction in the severity of anxiety and depression (32, 33). This evidence concerns the gene HCRTR2 and depressive disorder.